Although there is no evidence for transmission of mammalian retroviruses to humans via vaccine immunization, the allegations of contamination of oral poliovirus vaccines with human immunodeficiency virus (HIV) type 1 or a hypothetical progenitor virus from monkeys has created controversy and dispute regarding the origin of AIDS in humans. Twelve monovalent lots of live, attenuated oral poliovirus vaccine types 1, 2, and 3, which were released for use by a North American manufacturer between 1976-1989, were tested for the presence of HIV-1 and simian immunodeficiency virus (SIV). HIVISIV were not detected in these monovalent poliovirus vaccine lots with the reverse transcriptase assay, a general detection assay, and highly sensitive and specific polymerase chain reaction assays.
Live, attenuated oral poliovirus vaccines licensed in the United States are produced by infecting primary monkey kidney cells with Sabin virus strains according to the Code of Federal Regulations (CFR) [1] . Kidneys from each monkey are processed separately, and subsequent monolayer cell cultures are infected with Sabin polioviruses type 1, 2, or 3. The infected cell lysate is harvested within 72 h after infection, and monovalent virus pools are prepared. Live oral trivalent poliovirus vaccine is prepared by combining types 1, 2, and 3 monopools to produce trivalent vaccine containing the appropriate final titer of each virus type, as specified in the CFR [2] .
It has been speculated that the AIDS epidemic originated from a progenitor virus of human immunodeficiency virus (HIV) type 1 present in an early experimental polio vaccine used in late 1957 for a large-scale immunization trial in Africa [3 -6] . It has also been hypothesized that HIV-1 infection of homosexual men originated from contaminated polio vaccine [7] . Although there is no scientific evidence linking AIDS to polio vaccines [8] [9] [10] [11] [12] [13] , speculation that HIV-l was present in monkeys used in the production of the early polio vaccines has created controversy and dispute regarding the origin of the AIDS epidemic. In the present study, we analyzed 12 monopools of oral poliovirus vaccine, which were released for use by a North American manufacturer between 1976-1989, for the presence of HIV-1 and simian immunodeficiency virus (SIV). This period includes vaccine lots that were released before and after the first isolation of SIV in monkeys [14] .
Materials and Methods
Poliovirus monovalent vaccine lots. Twelve monopools of live, attenuated oral poliovirus vaccine types 1, 2, and 3 were retrieved from -20°C storage. We tested four lots of each type that was released for use by a North American manufacturer between 1976-1989, including lots that were released before and after the discovery of SIV in monkeys [14] . Vials of each lot were opened and aliquoted under sterile conditions. The aliquoted vaccine samples were stored at -80°C for retrovirus testing.
Reverse transcriptase (RT) assay. Monopoo1lots ofthe poliovirus vaccine were assayed for HIV/SIV using a new RT cocktail (unpublished data) that enhances the sensitivity of the RT assay for detection of HIV-1 and SIV over that of a published RT assay for HIV-1 [15] . Vaccine sample (10 J.LL) was incubated with 50 J.LL of the final cocktail mix, which contained 1.5 J.LCi of [ 32p]dTTP (>400 Ci/mmol; Amersham, Arlington Heights, IL), in a 1.5-mL screw-cap polypropylene tube (Sarstedt, Arlington, TX) for 2 h in a 37°e water bath. Reaction mixture (5 J.LL) was spotted in duplicate on DE81 paper (Whatman, Maidstone, UK) and air-dried. The paper was washed four times for 5 min each in 2 X standard saline citrate (SSe; I X SSC = 0.15 M NaCI plus 0.015 M Na citrate) at room temperature and two times for 1 min each in 95% ethanol. Results were obtained from autoradiography of the spotted samples and liquid scintillation counting of the spots.
To determine whether the components in the test samples inhibited or interfered with the RT assay and retrovirus detection, 9 J.LL of each monopool sample was spiked with 1 J.LL of a titered stock of HIV-1 (10 6 TCIDso/mL in human peripheral blood mononuclear cells [PBMC] ; provided by K. Clouse, FDA) and assayed for RT activity. As a control for the spiked vaccine samples, 1 J.LL of HIV-1 was added to 9 J.LL of complete medium (containing 10% serum). The sensitivity of the assay was determined by RT analysis * According to HIV2/SIV pol consensus sequences [27] and HIV-l pol and HIV-l gag consensus B sequences [29] . References t [28] , t [23] ,~ [24] .
of 10-fold serial dilutions of the HIV-l virus stock. Negative-range values for the assay were obtained using complete medium. By spiking HIV -1 into medium, positive-range values were obtained, and the range of variability in spiking was established. All samples were tested in at least two independent assays and spotted in duplicate. DNA polymerase chain reaction (PCR) analysis. Nucleic acid was extracted with phenol-chloroform from 0.4 mL ofeach vaccine monopool and precipitated with ethanol. The pellet was dissolved in 85 J..lL of 10 mM TRIS-HCI, pH 8.0. Three independent extractions were done for each of the 12 monopools, and nucleic acid from each extraction was assayed in two or more independent PCR reactions. Copy-number control panels were prepared to assess the sensitivity of detection by the PCR primers used in the study. For HIV-l, samples containing 0-50 copies were prepared by adding various amounts of cellular DNA from the 8E5 cell line, which contains a single copy of integrated HIV-1 per genome, [16] to 10 4 cell equivalents of DNA from an uninfected CEM clone 12D7 cell line [17] (provided by F. Kashanchi, NIH). For SIV, different amounts of BK28 DNA, cloned from SIVmm 251 virus (designated pBS/SIV b a m ; provided by J. Mullins, School of Medicine, University of Washington, Seattle) [18] were added to 10 5 cell equivalents of CEMI12D7 cell DNA to generate a control panel ranging from o to 1000 copies of viral DNA. Similarly, a control panel was prepared using a cloned DNA segment containing the pol region of a highly divergent SIV isolate from a stump-tailed macaque (SIVstm) [19] .
The primers used for the detection of HIV-1 and SIV DNA sequences were from highly conserved regions in the pol gene. Nucleotide sequences, positions of the oligonucleotide primer pairs and probes used in this study, and the expected size of their amplified fragments are indicated in table 1. The oligonucleotide primers and probes were synthesized on a DNA synthesizer (MilliGen, model 8700; Milligen/Biosearch, Marlboro, MA) according to the manufacturer's instructions. Twenty microliters of the nucleic acid solution from each monopool was used for DNA PCR in a total PCR reaction mix of 100 J..lL using Taq DNA polymerase (2.5 U) according to the manufacturer's instruction (Boehringer Mannheim, Indianapolis). Forty cycles of denaturation at 94°C for 1 min, annealing at 54°C for 1 min, and extension at 72°C for I min were done in a programmable thermal controller (MJ Research, Summit, NJ).
To increase the sensitivity of detection, PCR fragments were hybridized to internal oligonucleotide probes. Amplified product (10 J..lL) from the PCR reaction mixture was electrophoresed on 1% agarose gels and transferred to membranes (NYTRAN: Schleicher & Schuell, Keene, NH). Membranes were then prehybridized for 3 h at 42°C in l Ox Denhardt's solution (1 X is 0.02% each of bovine serum albumin, ficoll, and polyvinylpyrrolidone). 6x SSC, 1% SDS, and 100 J..lg/mL denatured salmon sperm DNA.
Hybridization was carried out overnight at 60°C in 6x sse and 1% SDS containing 10 6 cpm of end-labeled oligonucleotide probe per milliliter of hybridization mix (total volume, 20 ml.). The membranes were washed two times for 20 min each in 6:-< sse and 1% SDS at room temperature, once at 60°C for 20 min in 6>< SSC and 1% SDS, and once for 5 min at 60°C in I X sse and 1% SDS. The membranes were then air-dried and exposed to xray film at -70°C for short-and long-exposure times.
DNA control primers to detect the human ,B-actin gene (Clontech Laboratories, Palo Alto, CA) amplified a 838-bp DNA fragment, which was visualized by ethidium bromide staining of agarose gels.
RNA PCR analysis. Nucleic acid was prepared from 0.5 ml, of each vaccine monopool as described [20] and precipitated with isopropanol in the presence of carrier yeast tRNA (I flog/tube). The pelleted nucleic acid was resuspended in 100 flL of RNase-free water, and a lO-J..lL aliquot was used for RT-PCR. Two independent extracts of each of the 12 monopool lots were made, and t\VO lID 1996; 174 (December) or more PCR reactions were done on each preparation in a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT). To determine the sensitivity of PCR, samples containing HIV-1 viral RNAs ranging from 10 to 105 copies were prepared from medium containing various amounts of HIV-I MN virus (prepared in H9 cells). The RNA copy number per sample was calculated on the basis of the p24 antigen concentration [21] , which was determined using an HIV-1 p24 ELISA kit (DuPont Medical Products, Boston).
RNA PCR and hybridization were done as previously described [22] in the presence of uracil-N-glycosylase to avoid carry-over contamination in the PCR. The oligonucleotide primers and probe were synthesized on the basis of published sequences and are indicated in table 1. HIV-l gag primers SKl45 [23] and SK431 [24] were used to amplify a 142-bp fragment in an RT-PCR reaction volume of 60 ILL; 20 ILL of the amplified PCR reaction was then hybridized at 56°C for 1 h with 105 cpm of end-labeled SKI02 oligonucleotide probe [23] (Perkin-Elmer Cetus). Hybridization mixture (20 ILL) was electrophoresed on a 12% polyacrylamide gel in 0.5 X TRIS-borate-EDTA buffer and exposed to X-ray films at -70°C. Short-and long-exposure autoradiographs were developed.
The efficiency of RNA recovery from the poliovirus monopool lots type 1, 2, and 3 was verified by RT-PCR using poliovirusspecific primers designated as type 1 (nt 480), type 2 (nt 481), and type 3 (nt 472), respectively, as previously described [25, 26] . Extracted nucleic acid solution (50 ILL) was precipitated with isopropanol and resuspended in 40 ILL of cDNA reaction mixture [25] ; 8 ILL was used for PCR in a total volume of 30 ILL, and 8 ILL of the amplified material was resolved on a polyacrylamide gel. The results of the undigested PCR products are shown in figure 1B .
Results
RT assay. The monopool vaccine samples were analyzed for the presence of HIV/SIV using a new Mg++ -dependent RT assay that is 10-fold more sensitive for the detection of HIV-I and SIV (unpublished data) than a published RT assay for HIV -1 [15] . Sensitivity of detection in this assay was determined by analyzing 10-fold serial dilutions of an HIV -1 stock of known virus titer. The sensitivity of detection was < 10 TCID so (table 2) . The results were confirmed by inspection of the autoradiograph of the spotted samples prior to liquid scintillation counting of the spots. No radioactive signal was detected in the samples containing 1 or 0.1 TCID so on autoradiography (overnight exposure). Since the RT activity (counts per minute) of these samples was similar to that obtained with medium alone in other experiments (table 3), the RT activity at 1 or 0.1 TCID so was considered as the background negative value for the experiment. Similar results were obtained using three independently prepared dilution series. The results from two independent RT assays using one of the dilution series are shown in table 2. On the basis of these results, a sample was considered positive if the RT activity was at least 50% above the background RT activity, which was determined for each experiment.
No vaccine test samples showed RT activity above negative control values (table 3) . To determine whether components in the vaccine could inhibit or interfere with detection of retroviruses in the RT assay, each test sample was spiked with HIV-1 and compared with HIV-1 spiked in medium. The results indicated RT activity of the spiked virus was not reduced in the presence of the test samples (table 3) . Some sample-tosample variation was observed; however, the variability was within the SE of the postive control values. The range of positive and negative values for the RT assay is indicated as the mean ± SD of RT activity obtained for positive and negative control samples that were included in each independent assay of the test samples.
peR analysis. DNA PCR primers used to analyze the poliovirus vaccine lots for the presence of HIV-1 and SIV sequences were from the pol gene. The SIV primers designated as pol A and pol B (shown in table 1) were based on SIV and HIV-2 consensus sequences [27, 28] . These primer sequences are present in a wide variety of SIVs, including those isolated from Asian rhesus macaques (e.g., SIV mm 251) and West African monkeys, including green monkeys (SIVagm-sab) and sooty mangabeys (SIV smm) as well as in HIV-2 (e.g., HIV-2 Ro o ) [29] . The primers would be expected to amplify a 555-bp fragment from all of these viruses. Although a high degree of identity was present in the primer sequences of the aforementioned viruses, some mismatched bases were present: At most, a 4-base mismatch was seen in the case of primer A sequence in SIVm m 251.
The HIV-1 pol primer sequences are present with almost perfect identity in a large number of HI V-I isolates from different genotypes in the M group. In some cases, there was a single-base mismatch per primer [29] , but in all cases, a 138-bp fragment would be expected to be amplified in the M group. Of interest, this fragment size is maintained even in isolates belonging to other genotypes that differed in the primer sequences, such as the highly divergent 0 group. Analysis of copy-number control panels indicated that 1 copy of HIV -1 in 10 4 cells and 1 copy of BK28/SlVmm 251 in 105 cells could be detected (figure lA). Furthermore, the SIV pol primers could detect between 1 and 10 copies of SIV stm in 10 5 cells (Shahabuddin M, Khan AS; data not shown). It should be noted that SIV stm is a highly divergent SIV isolated from the stump-tailed macaque, which might have been acquired by cross-species transmission from an African sooty mangabey and may represent a possible progenitor of HIV-2 [19] . Analysis of the vaccine lots by DNA PCR indicated the absence of the l38-bp HIV-I-and the 555-bp SIV/HIV-2-specific fragments (figure lA). The presence of DNA in the nucleic acid preparations was confirmed by amplification of cellular ,B-actin DNA extracted from the sample.
The HIV-1 pol primer pair amplified a fragment from normal CEM/12D7 cells in the control panel that was larger in size than the HIV-1 virus -specific fragment; this was seen in the o copy lane on an overnight exposure of the autoradiograph (data not shown). On this exposure, the virus-specific bands were too intense for analysis. The larger-size fragment was probably of cellular origin and could not be due to HIV -I since the intensity of this fragment did not increase with the viral copy numbers. Some of the vaccine lots showed bands that were faintly detectable in long-exposure autoradiographs (7 days); however, these bands did not correspond in size to the expected HIV-1 fragment but were similar to the fragment amplified from normal uninfected cell DNA and, thus, were most likely due to nonspecific amplification of cellular DNA in the vaccines. Analysis of the samples for HI V-1 RNA using gag primers indicated the samples contained no detectable HIV-1 viral RNA even after long exposure of the autoradiograph (5 days; figure  IB) . The integrity of the RNA in the preparations was confirmed by demonstrating the presence of poliovirus RNAs in all of the test samples. Sensitivity of detection of HIV-I RNA by RT-peR was at the level of 10-100 copies , as determined by analyzing the copy number controls. Discussion NOTE. Data are mean :!: SD cprn/5 jiL spotted; calculated from 4 spots in 2 independent assays (2 spots /sample/assay). * Virus stock titer was 10 6 TCID ,o/mL in human peripheral blood mononuclear cells.
In this study, we analyzed 12 oral poliovirus monovalent vaccine lots, which were released for use in the United States between 1976-1989, for the presence of HIV-I and SIV/HIV- Table 3 . Reverse transcriptase (RT) analysis of poliovirus vaccine lots.
NOTE. Data are mean ± SD cprn/5 J-lL spotted. Results were confirmed by autoradiography. * 9 J-lL of vaccine sample + 1 J-lL of medium was tested. Mean was calculated from data of 4 spots from 2 independent assays (2 spots/sample/assay) except for lot 6, from which I spot was discounted due to nonspecific background determined by autoradiography.
t 9 J-lL of vaccine sample was spiked with 1 J-lL of HIV -1. Mean was calculated from data of 4 spots from 2 independent assays (2 spots/sample/ assay) except for lot 1, for which data are from 6 spots from 3 independent assays (2 spots/sample/assay).
t Negative control was 10 J-lL of medium; positive control was 1 J-lL of HIV-I + 9 J-lL of medium. Range of negative and positive values for assay was obtained as mean ± SD of RT activity of 6 negative and 6 positive samples tested in independent assays (2 spots/sample).
2. Our approach was to use a general retrovirus detection assay (RT) and specific, highly sensitive PCR assays in an attempt to detect the possible presence of novel and known retroviral contaminants in the test materials. Furthermore, DNA and RNA PCRs were done to analyze for integrated proviral sequences and viral RNAs, respectively. The PCR primers used in the analyses were selected from highly conserved regions of the viral genome to detect different isolates in the HIV-l and SIV/ HIV -2 groups. The results of this combination analysis indicated HIV /SIV was not detected in the monovalent vaccines. Our studies corroborate the results of others indicating the absence of HIV/SIV in oral polio vaccines. Garrett et al. [13] reported no evidence of HIV/SIV by PCR analysis in 15 pools of oral polio vaccines released for use between 1975-1984 by four manufacturers in Europe and North America. Ohta et al. [10] were unable to isolate SIV from 6 monovalent bulk stocks in culture studies. In addition, a summary of earlier studies on live oral poliovirus vaccines indicated that 17 lots were negative for RT activity and 5 for SIV isolation [9, 10] . been immunized with poliovirus vaccines are negative for HIV/ SIVantibodies [9, 10] .
Some have theorized the origin of AIDS in humans from oral polio vaccines by alleged contamination of vaccines with HIV-lor from a hypothetical progenitor virus from monkeys [3] [4] [5] [6] [7] ; however, scientific data do not provide support for these theories. In addition to the lack of detection of HIV/SIV by direct analyses of the vaccines (discussed above), the biology and genealogy of HIV-1 is not consistent with the speculations. There is no evidence for replication of HIV-lor SIV in monkey kidney cells. This was confirmed by the inability to isolate virus from kidneys of SIV-infected monkeys [9, 10, 13] . It was shown that trypsin, which is used in the preparation of monkey kidney cell cultures used in vaccine production, can inhibit HIV-1 infection under the conditions used for manufacture of the vaccine [13, 30] . The origin of HI V-I from an unknown progenitor virus present in an experimental polio vaccine was formally addressed by a scientific panel of experts that released a report disputing this theory [11] . They concluded that the HIV link with the experimental polio vaccine was highly unlikely.
In summary, our data show that HIV/SIV was not detected in 12 poliovirus monovalent vaccines, which were approved for release in the United States from 1976 to 1989, using techniques for the detection of multiple viral markers (i.e., DNA, RNA, and RT). These findings corroborate WHO's recommendations for the continued use of polio vaccines [8, 9] . To further assure the safety of the vaccine, WHO recommended that the tissues used in vaccine production be from monkeys demonstrated to be free of antibodies to SIV [31] . The use of retrovirus-free monkeys in the preparation of polio vaccines and the application of new and more sensitive screening procedures for testing novel retroviruses in the animals used in vaccine production can provide added assurance for the safety of these vaccines.
